Potentiation of therapeutic effects of nicotinic acid by pyridoxine in chronic schizophrenics.
D000328:Adult; D000613:Aminobutyrates / Q000378:metabolism; D014150:Antipsychotic Agents / Q000008:administration & dosage; D002170:Canada; D002986:Clinical Trials as Topic; D004357:Drug Synergism; D005260:Female; D006778:Hospitals, Psychiatric; D006801:Humans; D007902:Length of Stay; D008297:Male; D008715:Methionine / Q000378:metabolism; D008875:Middle Aged; D009539:Nicotinic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010640:Phenothiazines; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D011736:Pyridoxine / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D014364:Tryptophan / Q000378:metabolism
D000613:Aminobutyrates; D014150:Antipsychotic Agents; D009539:Nicotinic Acids; D010640:Phenothiazines; D010919:Placebos; D014364:Tryptophan; D008715:Methionine; D011736:Pyridoxine